Holen Sie sich die Stockscreener-App
2.46
4.65%
-0.12
Handel nachbörslich:
2.46
Schlusskurs vom Vortag:
$2.58
Offen:
$2.57
24-Stunden-Volumen:
6,319
Relative Volume:
0.01
Marktkapitalisierung:
$4.03M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-36.46M
KGV:
-1.025
EPS:
-2.4
Netto-Cashflow:
$-30.20M
1W Leistung:
-7.52%
1M Leistung:
+3.36%
6M Leistung:
-4.65%
1J Leistung:
-76.57%
1-Tages-Spanne:
$2.45
$2.6932
1-Wochen-Bereich:
$2.45
$2.6932
52-Wochen-Spanne:
$1.3137
$11.50
Alaunos Therapeutics Inc Stock (TCRT) Company Profile
Firmenname
Alaunos Therapeutics Inc
Sektor
Branche
Telefon
(346) 355-4099
Adresse
2617 BISSONNET ST, HOUSTON
Vergleichen Sie TCRT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TCRT
Alaunos Therapeutics Inc
|
2.46 | 4.36M | 0 | -36.46M | -30.20M | -2.40 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Alaunos Therapeutics Inc Stock (TCRT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-10-04 | Fortgesetzt | Wells Fargo | Overweight |
Alaunos Therapeutics Inc Aktie (TCRT) Neueste Nachrichten
Alaunos Therapeutics Secures $25M Equity Purchase Deal - MSN
Ziopharm: Q1 Earnings Snapshot - CT Insider
Alaunos Therapeutics (NASDAQ:TCRT) Trading Down 2.4% – Time to Sell? - Defense World
PMGC Capital announces filing to report 5.09% stake in Alaunos Therapeutics - TipRanks
PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. - GlobeNewswire
PMGC Capital Takes 5.09% Stake in Alaunos Therapeutics, Eyes Strategic Changes Including Fintech Expansion - Stock Titan
Alaunos Therapeutics (NASDAQ:TCRT) Trading Up 2.5% – Time to Buy? - Defense World
Alaunos Therapeutics announces board member resignation - Investing.com Australia
Alaunos Therapeutics announces board member resignation By Investing.com - Investing.com Canada
Form 8-KCurrent report - ADVFN
Alaunos Therapeutics Board Opts for Equity Compensation - TipRanks
Alaunos Therapeutics announces private placement of preferred stock By Investing.com - Investing.com Canada
Alaunos Therapeutics announces private placement of preferred stock - Investing.com
Alaunos Therapeutics And 2 Other Promising Penny Stocks To Watch - simplywall.st
Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Short Interest Down 12.5% in March - Defense World
11 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday SessionAllakos (NASDAQ:ALLK), Alumis (NASDAQ:ALMS) - Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Alaunos Therapeutics Inc. (TCRT) reports earnings - Quartz
Alaunos Therapeutics (NASDAQ:TCRT) Shares Down 6.5% – Here’s What Happened - Defense World
Lantheus acquires radiopharma CDMO Evergreen for up to $1bn - Pharmaceutical Technology
Alaunos Therapeutics (NASDAQ:TCRT) Stock Price Up 4% – Should You Buy? - Defense World
Update: Johnson & Johnson acquires Intra-Cellular Therapies - Pharmaceutical Technology
Light Horse emerges with $62m and Novartis partnership worth up to $1bn - Pharmaceutical Technology
Alaunos Therapeutics (NASDAQ:TCRT) Stock Price Down 0.5% – Time to Sell? - Defense World
TCRT stock touches 52-week low at $1.92 amid market challenges - Investing.com
Novartis acquires Kate Therapeutics to advance gene therapies - Pharmaceutical Technology
Ziopharm: Q3 Earnings Snapshot - San Francisco Chronicle
Alaunos Therapeutics Inc (TCRT) Quarterly 10-Q Report - qz.com
TCRT Stock Touches 52-Week Low at $1.96 Amid Market Challenges - Investing.com
After axing its sole clinical prospect last year, Alaunos cuts ties with Precigen - Fierce Biotech
Precigen Terminates License Agreement With Alaunos Therapeutics - MarketWatch
Genentech buys Regor’s CDK inhibitors in $850m deal - Clinical Trials Arena
VION Biosciences acquires Echelon Biosciences - Pharmaceutical Technology
TCRT stock touches 52-week low at $2.28 amid market challenges - Investing.com India
Eli Lilly inaugurates R&D facility in Boston, US - Pharmaceutical Technology
Alaunos Therapeutics announces 1-for-10 reverse stock split - Investing.com
Avenzo Therapeutics secures $150m to bolster oncology pipeline - Pharmaceutical Technology
Gilead concludes acquisition of CymaBay Therapeutics for $4.3bn - Pharmaceutical Technology
Alaunos Therapeutics Announces 1-for-15 Reverse Stock Split - TipRanks
Kyowa Kirin acquires Orchard Therapeutics for $477.6m - Pharmaceutical Technology
NAYA buys gene therapy company Florida Biotech for $20m - Clinical Trials Arena
Genentech signs nanoparticle deal worth up to $644m with GenEdit - Pharmaceutical Technology
BridGene and Galapagos partner for oncology drugs discovery - Pharmaceutical Technology
Novartis allies with Voyager to develop gene therapies in $1.3bn deal - Pharmaceutical Technology
Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today? - MSN
ELABPMGC Holdings Latest Stock News & Market Updates - Stock Titan
Syncona to buy biotechnology company Freeline Therapeutics - Pharmaceutical Technology
Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives - Yahoo Finance
Ascidian Therapeutics raises $40m to advance drug development - Pharmaceutical Technology
AstraZeneca and Cellectis partner to advance cell and gene therapies - Pharmaceutical Technology
Finanzdaten der Alaunos Therapeutics Inc-Aktie (TCRT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):